NFV NEWS

TMCNet:  Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report 2017 - Conventional Therapies Leave Considerable Unmet Needs - Research and Markets

[April 21, 2017]

Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report 2017 - Conventional Therapies Leave Considerable Unmet Needs - Research and Markets

Research and Markets has announced the addition of the "Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Acute Heart Failure (AHF) Therapeutics in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary research.

The report profiles 34 companies including many key and niche players such as:

  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Cardioretis AG (Switzerland)
  • CVie Therapeutics Limited (Taiwan)
  • Cytokinetics, Inc. (USA)
  • Merck & Co. (USA)
  • Novartis AG (Switzerland)
  • Orion Corporation (Finland)
  • PhaseBio Pharmaceuticals, Inc. (USA)

Key Topics Covered:

1. INDUSTRY OVERVIEW

2. MARKET DRIVERS, TRENDS & ISSUES

3. TREATMENT OF ACUTE HEART FAILURE (AHF)

4. ACUTE HEART FAILURE - THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS

5. RECENT INDUSTRY ACTIVITY

6. FOCUS ON SELECT PLAYERS

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 34 (including Divisions/Subsidiaries - 35)

- The United States (18)

- Japan (2)

- Europe (10)

- Germany (2)

- The United Kingdom (2)

- Italy (1)

- Rest of Europe (5)

- Asia-Pacific (Excluding Japan) (5)

For more information about this report visit http://www.researchandmarkets.com/research/fr2n9n/acute_heart


[ Back To NFVZone's Homepage ]